论文部分内容阅读
聚乙烯羟乙酸白细胞介素-2(PEGIL-2)是一种IL-2的缓释剂,其药代动力学与连续输注相同。本文用它维持治疗了7例(男4例,女3例),年龄19~65岁)第二次完全缓解(CR_2)中的急性髓细胞白血病(AML)患者。所有患者经蒽环类抗生素和阿糖胞苷诱导化疗获第一次完全缓解(CR_1)。为诱导CR_2,6/7例中有2例接受大剂量阿糖胞苷(Ara-C),1例柔红霉素+Ara-C,1例二羟二蒽酮+Ara-C,1例二羟二蒽酮+大剂量Ara-C,1例Menogaril方案化
PEGL-2 is a sustained release of IL-2 with the same pharmacokinetics as continuous infusion. This article uses it to maintain patients with acute myeloid leukemia (AML) in the second complete remission (CR 2) of 7 patients (4 males and 3 females, aged 19-65 years). All patients received first complete remission (CR_1) with anthracycline and cytarabine-induced chemotherapy. In order to induce CR_2, 6 of 6 patients received high dose of Ara-C, 1 of daunorubicin + Ara-C, 1 of dihydroxyldanthrone + Ara-C and 1 of 6 Dihydroxy diantrone + high dose Ara-C, 1 case of Menogaril regimen